Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-08

AUTHORS

Paul Emery, Marjolijn Van Keep, Steve Beard, Chris Graham, LaStella Miles, Steffen Marc Jugl, Praveen Gunda, Anna Halliday, Helena Marzo-Ortega

ABSTRACT

OBJECTIVE: To determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active ankylosing spondylitis (AS) who have not responded adequately to previous treatment with conventional care (CC; biologic-naïve population) or previous biologic therapy (biologic-experienced population). PERSPECTIVE AND SETTING: UK National Health Service (NHS). METHODS: The model was structured as a 3-month decision tree leading into a Markov model. Comparators were licensed tumour necrosis factor inhibitors (including available biosimilars) and CC in the biologic-naïve and biologic-experienced populations, respectively. Clinical parameters captured treatment response, short-term disease activity and patient functioning, as well as long-term structural disease progression. Utilities were derived from secukinumab trial data. List prices were used for all drugs. The cost year was 2017 and costs and outcomes were discounted at 3.5%. RESULTS: In the biologic-naïve population, secukinumab dominated adalimumab and certolizumab pegol. Incremental cost-effectiveness ratios (ICERs) versus other comparators were either below £10,000 per quality-adjusted life-year (QALY) gained or south-west ICERs that implied cost effectiveness of secukinumab. In biologic-experienced patients, the ICER for secukinumab versus CC was £4927 per QALY gained. Treatment response rates, short-term treatment effects, long-term radiographic progression and biologic acquisition costs were key model drivers. Scenario analysis found results to be robust to changes in model structural assumptions. Probabilistic analysis identified greater uncertainty in results in the biologic-naïve population. CONCLUSIONS: Even at list price, secukinumab appears to represent a cost-effective use of NHS resources for biologic-naïve and biologic-experienced patients with active AS. Further research on long-term radiographic progression outcomes would be valuable for future cost-effectiveness analyses in AS. More... »

PAGES

1015-1027

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40273-018-0675-9

DOI

http://dx.doi.org/10.1007/s40273-018-0675-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1104169922

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29797186


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Leeds Teaching Hospitals NHS Trust", 
          "id": "https://www.grid.ac/institutes/grid.415967.8", 
          "name": [
            "Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK", 
            "NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Emery", 
        "givenName": "Paul", 
        "id": "sg:person.01175471513.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01175471513.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "BresMed Netherlands BV, Utrecht, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van Keep", 
        "givenName": "Marjolijn", 
        "id": "sg:person.01215062721.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215062721.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "BresMed", 
          "id": "https://www.grid.ac/institutes/grid.482857.4", 
          "name": [
            "BresMed, Sheffield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Beard", 
        "givenName": "Steve", 
        "id": "sg:person.014016444733.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014016444733.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "RTI International", 
          "id": "https://www.grid.ac/institutes/grid.62562.35", 
          "name": [
            "RTI Health Solutions, Research Triangle Park, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Graham", 
        "givenName": "Chris", 
        "id": "sg:person.011016632446.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011016632446.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "RTI International", 
          "id": "https://www.grid.ac/institutes/grid.62562.35", 
          "name": [
            "RTI Health Solutions, Research Triangle Park, NC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miles", 
        "givenName": "LaStella", 
        "id": "sg:person.01225443552.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225443552.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jugl", 
        "givenName": "Steffen Marc", 
        "id": "sg:person.012612572155.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012612572155.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (India)", 
          "id": "https://www.grid.ac/institutes/grid.464975.d", 
          "name": [
            "Novartis Healthcare Private Limited, Hyderabad, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gunda", 
        "givenName": "Praveen", 
        "id": "sg:person.01064712533.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064712533.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.418607.c", 
          "name": [
            "Novartis Pharmaceuticals UK Ltd, Camberley, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Halliday", 
        "givenName": "Anna", 
        "id": "sg:person.0615147233.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615147233.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Leeds Teaching Hospitals NHS Trust", 
          "id": "https://www.grid.ac/institutes/grid.415967.8", 
          "name": [
            "Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK", 
            "NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marzo-Ortega", 
        "givenName": "Helena", 
        "id": "sg:person.01036451264.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036451264.52"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.jval.2015.02.016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002164347"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/ard.2008.091793", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003878294"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.38954.689583.de", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005182639"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1505066", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012917782"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2016.12195", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015296363"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/rheumatology/kew223", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021548690"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.38070", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024751947"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/ard.2011.151191", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026334144"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1017/s0266462308080203", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027367175"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2013-204055", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031555246"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/rheumatology/keh669", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032047738"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/14651858.cd008794.pub2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037802444"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3310/hta11280", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071138979"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3310/hta20090", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071139564"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-08", 
    "datePublishedReg": "2018-08-01", 
    "description": "OBJECTIVE: To determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active ankylosing spondylitis (AS) who have not responded adequately to previous treatment with conventional care (CC; biologic-na\u00efve population) or previous biologic therapy (biologic-experienced population).\nPERSPECTIVE AND SETTING: UK National Health Service (NHS).\nMETHODS: The model was structured as a 3-month decision tree leading into a Markov model. Comparators were licensed tumour necrosis factor inhibitors (including available biosimilars) and CC in the biologic-na\u00efve and biologic-experienced populations, respectively. Clinical parameters captured treatment response, short-term disease activity and patient functioning, as well as long-term structural disease progression. Utilities were derived from secukinumab trial data. List prices were used for all drugs. The cost year was 2017 and costs and outcomes were discounted at 3.5%.\nRESULTS: In the biologic-na\u00efve population, secukinumab dominated adalimumab and certolizumab pegol. Incremental cost-effectiveness ratios (ICERs) versus other comparators were either below \u00a310,000 per quality-adjusted life-year (QALY) gained or south-west ICERs that implied cost effectiveness of secukinumab. In biologic-experienced patients, the ICER for secukinumab versus CC was \u00a34927 per QALY gained. Treatment response rates, short-term treatment effects, long-term radiographic progression and biologic acquisition costs were key model drivers. Scenario analysis found results to be robust to changes in model structural assumptions. Probabilistic analysis identified greater uncertainty in results in the biologic-na\u00efve population.\nCONCLUSIONS: Even at list price, secukinumab appears to represent a cost-effective use of NHS resources for biologic-na\u00efve and biologic-experienced patients with active AS. Further research on long-term radiographic progression outcomes would be valuable for future cost-effectiveness analyses in AS.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s40273-018-0675-9", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1102812", 
        "issn": [
          "1170-7690", 
          "1179-2027"
        ], 
        "name": "PharmacoEconomics", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "36"
      }
    ], 
    "name": "Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK", 
    "pagination": "1015-1027", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "5c5ef79f08c5f8af771d9e21e2a899810cff592ba95f5fd9ae8c2b839eb3d5bf"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29797186"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9212404"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40273-018-0675-9"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1104169922"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40273-018-0675-9", 
      "https://app.dimensions.ai/details/publication/pub.1104169922"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000348_0000000348/records_54338_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs40273-018-0675-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40273-018-0675-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40273-018-0675-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40273-018-0675-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40273-018-0675-9'


 

This table displays all metadata directly associated to this object as RDF triples.

185 TRIPLES      21 PREDICATES      43 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40273-018-0675-9 schema:about anzsrc-for:14
2 anzsrc-for:1402
3 schema:author N81ec5c234ec44bceab69c94e236b2820
4 schema:citation https://doi.org/10.1001/jama.2016.12195
5 https://doi.org/10.1002/14651858.cd008794.pub2
6 https://doi.org/10.1002/art.38070
7 https://doi.org/10.1016/j.jval.2015.02.016
8 https://doi.org/10.1017/s0266462308080203
9 https://doi.org/10.1056/nejmoa1505066
10 https://doi.org/10.1093/rheumatology/keh669
11 https://doi.org/10.1093/rheumatology/kew223
12 https://doi.org/10.1136/annrheumdis-2013-204055
13 https://doi.org/10.1136/ard.2008.091793
14 https://doi.org/10.1136/ard.2011.151191
15 https://doi.org/10.1136/bmj.38954.689583.de
16 https://doi.org/10.3310/hta11280
17 https://doi.org/10.3310/hta20090
18 schema:datePublished 2018-08
19 schema:datePublishedReg 2018-08-01
20 schema:description OBJECTIVE: To determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active ankylosing spondylitis (AS) who have not responded adequately to previous treatment with conventional care (CC; biologic-naïve population) or previous biologic therapy (biologic-experienced population). PERSPECTIVE AND SETTING: UK National Health Service (NHS). METHODS: The model was structured as a 3-month decision tree leading into a Markov model. Comparators were licensed tumour necrosis factor inhibitors (including available biosimilars) and CC in the biologic-naïve and biologic-experienced populations, respectively. Clinical parameters captured treatment response, short-term disease activity and patient functioning, as well as long-term structural disease progression. Utilities were derived from secukinumab trial data. List prices were used for all drugs. The cost year was 2017 and costs and outcomes were discounted at 3.5%. RESULTS: In the biologic-naïve population, secukinumab dominated adalimumab and certolizumab pegol. Incremental cost-effectiveness ratios (ICERs) versus other comparators were either below £10,000 per quality-adjusted life-year (QALY) gained or south-west ICERs that implied cost effectiveness of secukinumab. In biologic-experienced patients, the ICER for secukinumab versus CC was £4927 per QALY gained. Treatment response rates, short-term treatment effects, long-term radiographic progression and biologic acquisition costs were key model drivers. Scenario analysis found results to be robust to changes in model structural assumptions. Probabilistic analysis identified greater uncertainty in results in the biologic-naïve population. CONCLUSIONS: Even at list price, secukinumab appears to represent a cost-effective use of NHS resources for biologic-naïve and biologic-experienced patients with active AS. Further research on long-term radiographic progression outcomes would be valuable for future cost-effectiveness analyses in AS.
21 schema:genre research_article
22 schema:inLanguage en
23 schema:isAccessibleForFree true
24 schema:isPartOf N686841fba81340a4a23fb68be86b3cfd
25 N6ab80d9bdae7437fa1a44fd423afd6ed
26 sg:journal.1102812
27 schema:name Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
28 schema:pagination 1015-1027
29 schema:productId N08b52316222e459fbc85f490ed520aeb
30 N1e6a840dc68b43578cde05949d1ce6e6
31 N4339d97809f64465814dbcff1251017b
32 Ne0da3202de404670adbef9278f8452c6
33 Nf754f46f8af5407b85da3190d9e09186
34 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104169922
35 https://doi.org/10.1007/s40273-018-0675-9
36 schema:sdDatePublished 2019-04-11T10:22
37 schema:sdLicense https://scigraph.springernature.com/explorer/license/
38 schema:sdPublisher Nbdd460e725d24523ac503070339d7e0b
39 schema:url https://link.springer.com/10.1007%2Fs40273-018-0675-9
40 sgo:license sg:explorer/license/
41 sgo:sdDataset articles
42 rdf:type schema:ScholarlyArticle
43 N08b52316222e459fbc85f490ed520aeb schema:name readcube_id
44 schema:value 5c5ef79f08c5f8af771d9e21e2a899810cff592ba95f5fd9ae8c2b839eb3d5bf
45 rdf:type schema:PropertyValue
46 N1e6a840dc68b43578cde05949d1ce6e6 schema:name pubmed_id
47 schema:value 29797186
48 rdf:type schema:PropertyValue
49 N26645885175e4a28b32b95710e05eee2 rdf:first sg:person.012612572155.70
50 rdf:rest Neabdba3a54694875b1da24fed92f03cb
51 N4339d97809f64465814dbcff1251017b schema:name doi
52 schema:value 10.1007/s40273-018-0675-9
53 rdf:type schema:PropertyValue
54 N4d766419709b4483ab286f934c4f0b45 rdf:first sg:person.01225443552.51
55 rdf:rest N26645885175e4a28b32b95710e05eee2
56 N4ec989b9ad3d4e6d9ab6b10f2bc180e9 rdf:first sg:person.01215062721.00
57 rdf:rest N6885e48cc9354d84860b67a29e51ecce
58 N55e03fcd0878453782cd5398dc656e27 schema:name BresMed Netherlands BV, Utrecht, The Netherlands
59 rdf:type schema:Organization
60 N686841fba81340a4a23fb68be86b3cfd schema:volumeNumber 36
61 rdf:type schema:PublicationVolume
62 N6885e48cc9354d84860b67a29e51ecce rdf:first sg:person.014016444733.26
63 rdf:rest Nf34818e5b3d94099b6ab0c736b43d2cb
64 N6ab80d9bdae7437fa1a44fd423afd6ed schema:issueNumber 8
65 rdf:type schema:PublicationIssue
66 N81ec5c234ec44bceab69c94e236b2820 rdf:first sg:person.01175471513.15
67 rdf:rest N4ec989b9ad3d4e6d9ab6b10f2bc180e9
68 N95fca74538e44615b7feb9abf89c535c rdf:first sg:person.01036451264.52
69 rdf:rest rdf:nil
70 Naaecba9eb8924a4cb36468dcf23c6a7e rdf:first sg:person.0615147233.96
71 rdf:rest N95fca74538e44615b7feb9abf89c535c
72 Nbdd460e725d24523ac503070339d7e0b schema:name Springer Nature - SN SciGraph project
73 rdf:type schema:Organization
74 Ne0da3202de404670adbef9278f8452c6 schema:name nlm_unique_id
75 schema:value 9212404
76 rdf:type schema:PropertyValue
77 Neabdba3a54694875b1da24fed92f03cb rdf:first sg:person.01064712533.04
78 rdf:rest Naaecba9eb8924a4cb36468dcf23c6a7e
79 Nf34818e5b3d94099b6ab0c736b43d2cb rdf:first sg:person.011016632446.35
80 rdf:rest N4d766419709b4483ab286f934c4f0b45
81 Nf754f46f8af5407b85da3190d9e09186 schema:name dimensions_id
82 schema:value pub.1104169922
83 rdf:type schema:PropertyValue
84 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
85 schema:name Economics
86 rdf:type schema:DefinedTerm
87 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
88 schema:name Applied Economics
89 rdf:type schema:DefinedTerm
90 sg:journal.1102812 schema:issn 1170-7690
91 1179-2027
92 schema:name PharmacoEconomics
93 rdf:type schema:Periodical
94 sg:person.01036451264.52 schema:affiliation https://www.grid.ac/institutes/grid.415967.8
95 schema:familyName Marzo-Ortega
96 schema:givenName Helena
97 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036451264.52
98 rdf:type schema:Person
99 sg:person.01064712533.04 schema:affiliation https://www.grid.ac/institutes/grid.464975.d
100 schema:familyName Gunda
101 schema:givenName Praveen
102 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064712533.04
103 rdf:type schema:Person
104 sg:person.011016632446.35 schema:affiliation https://www.grid.ac/institutes/grid.62562.35
105 schema:familyName Graham
106 schema:givenName Chris
107 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011016632446.35
108 rdf:type schema:Person
109 sg:person.01175471513.15 schema:affiliation https://www.grid.ac/institutes/grid.415967.8
110 schema:familyName Emery
111 schema:givenName Paul
112 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01175471513.15
113 rdf:type schema:Person
114 sg:person.01215062721.00 schema:affiliation N55e03fcd0878453782cd5398dc656e27
115 schema:familyName Van Keep
116 schema:givenName Marjolijn
117 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215062721.00
118 rdf:type schema:Person
119 sg:person.01225443552.51 schema:affiliation https://www.grid.ac/institutes/grid.62562.35
120 schema:familyName Miles
121 schema:givenName LaStella
122 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225443552.51
123 rdf:type schema:Person
124 sg:person.012612572155.70 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
125 schema:familyName Jugl
126 schema:givenName Steffen Marc
127 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012612572155.70
128 rdf:type schema:Person
129 sg:person.014016444733.26 schema:affiliation https://www.grid.ac/institutes/grid.482857.4
130 schema:familyName Beard
131 schema:givenName Steve
132 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014016444733.26
133 rdf:type schema:Person
134 sg:person.0615147233.96 schema:affiliation https://www.grid.ac/institutes/grid.418607.c
135 schema:familyName Halliday
136 schema:givenName Anna
137 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615147233.96
138 rdf:type schema:Person
139 https://doi.org/10.1001/jama.2016.12195 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015296363
140 rdf:type schema:CreativeWork
141 https://doi.org/10.1002/14651858.cd008794.pub2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037802444
142 rdf:type schema:CreativeWork
143 https://doi.org/10.1002/art.38070 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024751947
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1016/j.jval.2015.02.016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002164347
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1017/s0266462308080203 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027367175
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1056/nejmoa1505066 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012917782
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1093/rheumatology/keh669 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032047738
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1093/rheumatology/kew223 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021548690
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1136/annrheumdis-2013-204055 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031555246
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1136/ard.2008.091793 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003878294
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1136/ard.2011.151191 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026334144
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1136/bmj.38954.689583.de schema:sameAs https://app.dimensions.ai/details/publication/pub.1005182639
162 rdf:type schema:CreativeWork
163 https://doi.org/10.3310/hta11280 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071138979
164 rdf:type schema:CreativeWork
165 https://doi.org/10.3310/hta20090 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071139564
166 rdf:type schema:CreativeWork
167 https://www.grid.ac/institutes/grid.415967.8 schema:alternateName Leeds Teaching Hospitals NHS Trust
168 schema:name Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
169 NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK
170 rdf:type schema:Organization
171 https://www.grid.ac/institutes/grid.418607.c schema:alternateName Novartis (United Kingdom)
172 schema:name Novartis Pharmaceuticals UK Ltd, Camberley, Surrey, UK
173 rdf:type schema:Organization
174 https://www.grid.ac/institutes/grid.419481.1 schema:alternateName Novartis (Switzerland)
175 schema:name Novartis Pharma AG, Basel, Switzerland
176 rdf:type schema:Organization
177 https://www.grid.ac/institutes/grid.464975.d schema:alternateName Novartis (India)
178 schema:name Novartis Healthcare Private Limited, Hyderabad, India
179 rdf:type schema:Organization
180 https://www.grid.ac/institutes/grid.482857.4 schema:alternateName BresMed
181 schema:name BresMed, Sheffield, UK
182 rdf:type schema:Organization
183 https://www.grid.ac/institutes/grid.62562.35 schema:alternateName RTI International
184 schema:name RTI Health Solutions, Research Triangle Park, NC, USA
185 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...